Spero Therapeutics (SPRO) Receivables - Net (2023 - 2025)

Spero Therapeutics (SPRO) has 3 years of Receivables - Net data on file, last reported at $25.4 million in Q4 2025.

• For the quarter ending Q4 2025, Receivables - Net fell 48.66% year-over-year to $25.4 million; the trailing twelve-month figure through Dec 2025 stood at $25.4 million (down 48.66% YoY), and the FY2025 full-year result was $25.4 million, down 48.66% from the prior year.
• Receivables - Net for Q4 2025 stood at $25.4 million, up from $868000.0 in the prior quarter.
• Across five years, Receivables - Net topped out at $50.8 million in Q2 2024 and bottomed at $868000.0 in Q3 2025.
• The 3-year median for Receivables - Net is $49.2 million (2023), against an average of $35.9 million.
• The widest annual swing landed in 2024, when Receivables - Net advanced 0.49%; it then plunged 98.28% in 2025.
• A 3-year view of Receivables - Net shows it stood at $49.2 million in 2023, then increased by 0.49% to $49.4 million in 2024, then tumbled by 48.66% to $25.4 million in 2025.
• The last three Receivables - Net figures came in at $25.4 million (Q4 2025), $868000.0 (Q3 2025), and $24.5 million (Q2 2025), per Business Quant data.

Peer Comparison